Oncology - Bankstown Hospital - Grand Rounds - Further Reading - LibGuides at South Western Sydney Local Health District

SWSLHD Research News

Check out the SWSLHD Research News LibGuide!

Introduction

Welcome to the Grand Rounds Further Reading List, Oncology edition, brought to you by the Clinical Library, on Level 4, next to the Auditorium.

This library guide is to help support you in your professional development. Please give us feedback so we can improve this list in the future.

Some sections are under construction and will be ready later in the year. If you are presenting at a later Grand Rounds, please contact lynne.roberts3@health.nsw.gov.au and tell us about the content of your paper so we can add appropriate resources to the list for when you present your paper.

If you have any questions, please contact the Clinical Library on 9722 8250 or email SWSLHD-BankstownLibrary@health.nsw.gov.au or visit us Monday to Fridays, 8.30am - 5.00pm.

Journal Articles

Lee, H. Y., et al. (2021). "Clinical characteristics and survival of patients concurrently diagnosed with lung cancer and active pulmonary tuberculosis."https://assets.researchsquare.com/files/rs-279237/v1/5340f24a-94f7-4665-bde9-252c52595ba3.pdf?c=1631877735

Abstract:

Background: Active pulmonary tuberculosis (TB) occasionally coexists with lung cancer. However, the clinical and radiologic characteristics of this co-occurrence have not been fully evaluated.

Methods: Patients diagnosed with lung cancer and active pulmonary TB from January 2009 to December2017 in four hospitals of the Catholic University of Korea were retrospectively reviewed. The clinical characteristics, including the TB diagnosis methods, lung cancer pathology, staging, initial radiographic features, and survival were analyzed and compared to 575 lung cancer patients without active pulmonary TB from the same hospitals.

Results: Forty-eight (0.48%) of the 9,936 lung cancer patients had active pulmonary TB confirmed by positive culture results or polymerase chain reaction analysis for M. tuberculosis at the time of the initial cancer diagnosis. The majority of the patients (95.9%) had non-small cell lung cancer and 56.2% of the lung cancers were located in the both upper lobes. In the initial computed tomography, the most frequent

findings were a mass-like lesion (79.2%) and separate nodules (75%). When compared to lung cancer

patients without TB, the body mass index (BMI) was lower (21.4 vs. 23.1, P = 0.001) in patients with TB.

Moreover, the lung cancer patients with TB had advanced clinical stages compared to patients without

TB; T3-4 (70.9% vs. 50.6%, P = 0.002), N2-3 (85.2% vs. 55.6%, P < 0.001); M1 (65.9% vs. 44.5%, P = 0.007).

Patients' age, histology, location, and the presence of epidermal growth factor receptor mutations were

not statistically different between the two groups. Interestingly, lung cancer with TB was associated with

lower mortality (hazard ratio = 0.35, 95% CI: 0.2 1– 0.60).

Nakahama, K., et al. (2022). "Safe Concurrent Use of Anti-tuberculosis Drugs and Pembrolizumab in a Patient with Non-small-cell Lung Cancer Who Was Infected with Mycobacterium tuberculosis." Internal Medicine 61(7): 1039-1042 FULL TEXT @SWSLHD LIBRARIES

Abstract:

A 68-year-old Japanese man was diagnosed with lung adenocarcinoma stage IVB. We introduced a first-line chemotherapy of four cycles of carboplatin and pemetrexed and pembrolizumab, followed by pemetrexed and pembrolizumab maintenance therapy. Approximately four months after anticancer therapy, a small nodule appeared in the right peripheral S3 lesion. After five months, the nodule was confirmed as a Mycobacterium tuberculosis (TB) nodule. We initiated anti-TB therapy without stopping pembrolizumab, and the right S3 nodule shrank immediately. This report supports the concurrent use of anti-TB treatment with an immune checkpoint inhibitor when the TB infection area is limited.

Polistina, G., et al. (2020). "Pulmonary tuberculosis pre XDR and lung cancer: double trouble." Chest 157(6): A56 BANKSTOWN HOSPITAL PDF AT URL https://journal.chestnet.org/article/S0012-3692(20)30940-5/fulltext

Abstract:

Purpose: Evidence of pulmonary tuberculosis and lung cancer as a comorbidity has been widely reported in many studies. Lung cancer is known to occur on scars and post tuberculosis fibrotic areas. Literature on timing of treatment of both pathologies is contradictory. Our case report shows the possibility of simultaneously therapeutic scheme with both pathologies.

Methods: A 42 years old man. Ukrainian active smoker was admitted in emergency department for lumbar pain and paraplegia onset on wellness. History of multi drugs resistant (MDR) pulmonary tuberculosis in 2016. The CT scan showed: “right paratracheal lesion confluent invading the right conjugation foramina”. FNAB CT on right paravertebral lesion was performed.

Results: BAAR sputum research was negative on 3 samples. XpertMTB®/Ref. genotyping was positive 1 out of 3 samples. Culture resulted positive. Due the clinical conditions we decide to start specific anti-tuberculosis therapy. Histological results from FNAB CT showed neoplastic cell from SMALL CELL LUNG CARCINOMA. We decided with the oncology unit to add anti neoplastic therapy simultaneously. During therapy, culture became negative on two samples.

Conclusions: Several studies have shown that active tuberculosis is found in 2-5% of cases of lung cancer while lung cancer occurs in 1-2% of active tuberculosis due to the possible carcinogenic role played by chronic inflammation. We could not find in the Literature correct timing for therapeutic approach of the two simultaneous pathologies.

Clinical implications: This case report demonstrates that in case of MDR active tuberculosis infection and concomitant neoplastic pathology, it is possible to adopt a simultaneous therapeutic scheme as soon as possible.

Tang, W., et al. (2022). "Differences in CT imaging signs between patients with tuberculosis and those with tuberculosis and concurrent lung cancer." American Journal of Translational Research 14(9): 6234 PDF AT URL https://e-century.us/files/ajtr/14/9/ajtr0139046.pdf

Abstract:

Objective: The purpose of this study was to compare the differences in imaging features between patients with pulmonary tuberculosis (TB) alone and patients with TB complicated with lung cancer (LCA) as well as to investigate the diagnostic value of CT in these two groups. Methods: In this retrospective study, 110 patients with confirmed TB admitted to the Second Affiliated Hospital of Hainan Medical University from March 2020 to April 2021 were collected and divided into TB+LCA group (50 cases, diagnosed with TB complicated with lung cancer) and TB group (60 cases, diagnosed with TB alone) according to actual diagnosis. The CT results of both groups were analyzed by the same group of physicians in a double-blind manner. The diagnostic value of CT for TB alone and TB complicated with lung cancer was calculated. The differences in CT imaging characteristics between the two groups were investigated. The differences in the structural characteristics of para-cancerous tissue between the two groups were analyzed. Results: The diagnostic accuracy of CT was 91.67% in TB patients (55/60) and 92.00% in TB+LCA

patients (46/50) without significant difference (X2=0.004, P=0.949). The detection rate of spiculation, lobulation and cavitation in TB+LCA group was significantly higher than that in TB group (P<0.05), and the distribution, size and wall thickness of cavitation varied significantly between the two groups (P<0.05). Patients in TB group had higher percentage of mediastinal lymph node calcification, peripheral satellite lesion, and mediastinal lymph node enlargement around the TB lesions compared with those in TB+LCA group (P<0.05). Conclusion: CT has certain application value in differentiating TB alone from TB complicated with lung cancer, and there are many similarities in the imaging features of the two conditions. CT can be considered as a preliminary means of differential diagnosis of TB complicated with lung cancer, which is helpful to the primary screening diagnosis of lung cancer.

Ye, M.-F., et al. (2020). "Efficacy and safety of concurrent anti-tuberculosis treatment and chemotherapy in lung cancer patients with co-existent tuberculosis." Annals of Translational Medicine 8(18) FULL TEXT AT URL https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576042/

Abstract:

Background: This retrospective study evaluated the safety and efficacy of concurrent anti-tuberculosis (TB) and chemotherapy treatment in patients with advanced lung cancer and active TB.

Methods: We retrospectively analyzed patients who were first diagnosed with advanced lung cancer and received first-line chemotherapy in Guangzhou Chest Hospital from 2015 to 2017. Patients were categorized into two groups (2:1): lung cancer patients without active TB (Group A), and lung cancer patients with active TB (Group B). Primary endpoints included adverse events (AEs), objective response rate (ORR), time to treatment failure, and overall survival (OS).

Results: A total of 99 patients were eligible (Group A, n=66; Group B, n=33). Grade ≥3 treatment-related AEs, primarily hematologic toxicity, occurred in 39.4% and 51.5% of patients in Groups A and B, respectively. The hypohepatia in both groups was generally at grade 1 or 2, with similar incidences (26% and 27%, respectively). After two cycles of chemotherapy, the ORR was 42.4% and 33.3% in Group A and B, respectively (P=0.383). The median time to treatment failure (TTF) was 7.0 and 5.6 months for Groups A and B, respectively (P=0.175). The median OS was 17.0 and 14.0 months for Groups A and B, respectively (P=0.312). After 3 months of anti-TB treatment, all patients achieved sputum acid-fast bacilli (AFB) smear conversion and absorption on imaging, and the end of follow-up observed no recurrence.

Conclusions: Concurrent anti-TB and chemotherapy treatment did not increase hematological toxicity or hypohepatia in lung cancer patients with pulmonary TB.

Books

Clinical Gynecologic Oncology by Philip J. DiSaia; William T. Creasman; Robert S. Mannel; Scott McMeekin; David G. Mutch
Call Number: BANKSTOWN Medical Library WP 145/CLI/9
ISBN: 9780323400671
Publication Date: 2017
The most readable, most comprehensive book in its field, Clinical Gynecologic Oncology, 9th Edition is the leading reference for diagnosis and treatment of gynecologic cancers - a must-have reference for improving outcomes and providing effective care. A "who's who" list of contributing authors, under the editorial direction of Drs. Philip DiSaia and William Creasman, provides expert guidance on clinical presentations and management, now fully up to date with a brand-new design for faster, easier reference. Contains useful appendices covering staging, screening, nutritional therapy, toxicity criteria, blood component therapy, and radiation therapy. Expert ConsultT eBook version included with purchase. This enhanced eBook experience allows you to search all of the text, figures, videos, and references from the book on a variety of devices. Covers hot topics such as multi-panel genetic testing, target therapies, sentinel node concept in endometrial cancer and vulvar cancer, and robotic surgery. Updates include new quick-reference features such as key point boxes with bulleted lists, highlighted key text, enhanced chapter outlines, and a brand-new design throughout. Includes up-to-date references and algorithms, making this text a comprehensive resource for clinical practice, personal study, and exam review. Helps you take advantage of the latest advances in early detection and improved treatment options for gynecologic cancers, especially uterine and cervical cancers.
Handbook of Breast Cancer and Related Breast Disease by Katherine H. R. Tkaczuk (Editor); Susan B. Kesmodel (Editor); Steven J. Feigenberg (Editor)
Call Number: BANKSTOWN Medical Library WP 870/HAN/1
ISBN: 9781620700990
Publication Date: 2016
Handbook of Breast Cancer and Related Breast Disease is a practical guide to the management of patients with breast malignancies and related non-neoplastic lesions. Written and edited by leading experts, this handbook focuses on the application of conventional and novel treatment strategies to the care of patients with nonmalignant breast disease and all stages of breast cancer. The handbook is organized chronologically, from screening, through diagnosis and management, to survivorship care and related medical issues. The bulk of these chapters provide evidence-based treatment strategies for all patient subsets, including how to manage patients with high risk breast lesions, invasive breast carcinoma at each stage, and with all known molecular subtypes of breast cancer. Surgical, radiation, and medical treatment options are all discussed for each stage of breast cancer including treatment approaches in pregnancy and for high risk lesions and phyllodes. This handbook is a comprehensive yet concise resource for residents, fellows, and early-career practitioners. Community oncologists, breast surgeons, radiation oncologists, primary care practitioners, and OBGYNs will also find its concise review of new research and procedures to be very useful in this dynamic field of medicine. KEY FEATURES: Discusses genomic testing in management of early stage breast cancerCovers adjuvant and neoadjuvant treatment approachesIncludes short clinical trial reviews for quick update of study endpoints and results for reference in management of breast cancerOutlines strategies for survivorship issuesKey points in each chapter highlight management pearls and summarize other important concepts and clinical recommendations
Oxford Textbook of Oncology by David J. Kerr (Editor); Daniel G. Haller (Editor); Cornelis J. H. van de Velde (Editor); Michael Baumann (Editor); Nagahiro Saijo (Editor)
Call Number: BANKSTOWN Medical Library QZ 200/KER/3
ISBN: 9780199656103
Publication Date: 2016
Written and edited by internationally recognised leaders in the field, the new edition of the Oxford Textbook of Oncology has been fully revised and updated, taking into consideration the advancements in each of the major therapeutic areas, and representing the multidisciplinary management ofcancer.Structured in six sections, the book provides an accessible scientific basis to the key topics of oncology, examining how cancer cells grow and function, as well as discussing the aetiology of cancer, and the general principles governing modern approaches to oncology treatment. The book examinesthe challenges presented by the treatment of cancer on a larger scale within population groups, and the importance of recognising and supporting the needs of individual patients, both during and after treatment.A series of disease-oriented, case-based chapters, ranging from acute leukaemia to colon cancer, highlight the various approaches available for managing the cancer patient, including the translational application of cancer science in order to personalise treatment. The advice imparted in these caseshas relevance worldwide, and reflects a modern approach to cancer care.TheOxford Textbook of Oncology provides a comprehensive account of the multiple aspects of best practice in the discipline, making it an indispensable resource for oncologists of all grades and subspecialty interests.
Textbook of Uncommon Cancer by Derek Raghavan (Editor); Manmeet S. Ahluwalia (Editor); Charles D. Blanke (Editor); Jubilee Brown (Editor); Edward S. Kim (Editor); Gregory H. Reaman (Editor); Mikkael A. Sekeres (Editor)
Call Number: BANKSTOWN Medical Library QZ 200/TEX/5
ISBN: 9781119196204
Publication Date: 2017
The fifth edition of the only comprehensive text dealing exclusively with rare or infrequently encountered malignancies in adults and children is an essential resource for any clinical oncologist. Encompasses all the information needed to diagnose and manage uncommon cancers, an area where advice and guidance is typically scarce Fully revised with new material and an evidence-based, teach-by-example approach Provides insight on real-world decision making in the clinical setting Edited and authored by a highly experienced and senior team of medical oncologists, radiation oncologists, and other specialists, giving a balanced and complete overview Extensively illustrated in full color throughout, including heat maps to show gene expression

E-Books

Abeloff's Clinical Oncology by John E. Niederhuber; James O. Armitage; James H. Doroshow; Michael B. Kastan; Joel E. Tepper
Call Number: CIAP Journals (log in required for home access)
ISBN: 9781455728657
Publication Date: 2013
Practical and clinically focused, Abeloff's Clinical Oncology is a trusted medical reference book designed to capture the latest scientific discoveries and their implications for cancer diagnosis and management of cancer in the most accessible manner possible. Abeloff's equips everyone involved - from radiologists and oncologists to surgeons and nurses - to collaborate effectively and provide the best possible cancer care. Select the most appropriate tests and imaging studies for cancer diagnosis and staging of each type of cancer, and manage your patients in the most effective way possible by using all of the latest techniques and approaches in oncology. Enhance your understanding of complex concepts with a color art program that highlights key points and illustrates relevant scientific and clinical problems. Stay at the forefront of the latest developments in cancer pharmacology, oncology and healthcare policy, survivorship in cancer, and many other timely topics. See how the most recent cancer research applies to practice through an increased emphasis on the relevance of new scientific discoveries and modalities within disease chapters. Streamline clinical decision making with abundant new treatment and diagnostic algorithms as well as concrete management recommendations. Take advantage of the collective wisdom of preeminent multidisciplinary experts in the field of oncology, including previous Abeloff's editors John E. Niederhuber, James O. Armitage, and Michael B. Kastan as well as new editors James H. Doroshow from the National Cancer Institute and Joel E. Tepper of Gunderson & Tepper: Clinical Radiation Oncology. Quickly and effortlessly access the key information you need with the help of an even more user-friendly, streamlined format. Access the complete contents anytime, anywhere at Expert Consult, and test your mastery of the latest knowledge with 500 online multiple-choice review questions. Your purchase entitles you to access the web site until the next edition is published, or until the current edition is no longer offered for sale by Elsevier, whichever occurs first. If the next edition is published less than one year after your purchase, you will be entitled to online access for one year from your date of purchase. Elsevier reserves the right to offer a suitable replacement product (such as a downloadable or CD-ROM-based electronic version) should access to the web site be discontinued.
Precision Medicine in Oncology by James A. Radosevich (Editor); Bulent Aydogan (Editor)
Call Number: ProQuest E-Book Central database (login required)
ISBN: 9781119432449
Publication Date: 2020-11-02
Precision medicine takes into account each patient's specific characteristics and requirements to arrive at treatment plans that are optimized towards the best possible outcome. As the field of oncology continues to advance, this tailored approach is becoming more and more prevalent, channelling data on genomics, proteomics, metabolomics and other areas into new and innovative methods of practice. Precision Medicine in Oncology draws together the essential research driving the field forward, providing oncology clinicians and trainees alike with an illuminating overview of the technology and thinking behind the breakthroughs currently being made. Topics covered include: Biologically-guided radiation therapy Informatics for precision medicine Molecular imaging Biomarkers for treatment assessment Big data Nanoplatforms Casting a spotlight on this emerging knowledge base and its impact upon the management of tumors, Precision Medicine in Oncology opens up new possibilities and ways of working - not only for oncologists, but also for molecular biologists, radiologists, medical geneticists, and others.
Radiation Oncology Management Decisions by K. S. Clifford Chao; Carlos A. Perez; Tony J. C. Wang
Call Number: ProQuest E-Book Central database (login required)
ISBN: 9781496391094
Publication Date: 2018
Updated with details on the newest therapies and sporting a new full-color design, this latest edition of Radiation Oncology: Management Decisions continues to offer comprehensive guidance for residents as well as radiation oncologists already in professional practice. You'll discover the latest treatment plans for numerous cancer sites and tumor types, including the mouth and sinus, gastrointestinal areas, lungs, bones, and blood. Concise, easy-to-read material you can use in a clinical setting immediately with patients! Combines comprehensive overviews of basic concepts with the latest radiologic treatment regimens for a wide variety of tumor types and cancer sites. Now in full color! Bursting with hundreds of illustrations, figures, and images to illuminate visually important and state-of-the-art techniques. Heavily bulleted content format and to-the-point writing style makes content easy to digest and use with patients quickly. Chapters that address tumor- or site-specific treatments cover screening, assessment, staging, therapeutic developments, and other key information. Features an up-to-date list of commonly prescribed drugs--streamlined for easier reading--and coverage of the latest pain management and palliative treatments. Enhance Your eBook Reading Experience Read directly on your preferred device(s), such as computer, tablet, or smartphone. Easily convert to audiobook, powering your content with natural language text-to-speech.
Precision Oncology and Cancer Biomarkers by Anne Bremer (Editor); Roger Strand (Editor)
Call Number: ProQuest E-Book Central database (login required)
ISBN: 9783030926113
Publication Date: 2022
This open access book reflects on matters of social and ethical concern raised in the daily practices of those working in and around precision oncology. Each chapter addresses the experiences, concerns and issues at stake for people who work in settings where precision oncology is practiced, enacted, imagined or discussed. It subsequently discusses and analyses bioethical dilemmas, scientific challenges and economic trade-offs, the need for new policies, further technological innovation, social work, as well as phenomenological research. This volume takes a broad actor-centred perspective as, whenever cancer is present, the range of actors with issues at stake appears almost unlimited. This perspective and approach opens up the possibility for further in-depth and diverse questions, posed by the actors themselves, such as: How are cancer researchers navigating biological uncertainties? How do clinicians and policy-makers address ethical dilemmas around prioritisation of care? What are the patients' experiences with, and hopes for, precision oncology? How do policy-makers and entrepreneurs envisage precision oncology? These questions are of great interest to a broad audience, including cancer researchers, oncologists, policy-makers, medical ethicists and philosophers, social scientists, patients and health economists.

Journals

Asia-Pacific Journal of Clinical Oncology
Call Number: CIAP Journals (log in required for home access)
Publication Date: 03/2005 - Current
Cancer ( John Wiley and Sons , Inc. )
Call Number: CIAP Journals (log in required for home access)
Publication Date: 05/2005 - Current
Sarcoma
Call Number: CIAP Journals (log in required for home access)
Publication Date: 01/2014 - Current

Web Resources

eviQ : cancer treatments online

A free resource of evidence-based, consensus driven cancer treatment protocols and information for use at the point of care. eviQ is developed for the Australian context and supports health professionals in the delivery of cancer treatments.

Cancer Drugs Interactions.

Cancer iChart - available via CIAP

Podcasts and Media

Compassion Revolution

Dive into what it means to practice love, compassion, courage and all the hard work of showing up to shape a compassion revolution across health care.

Join the Compassion Revolution Podcast on Apple or Google Podcast, or wherever you listen to your podcasts.

The Geeky Medics

Discussions with some of the most fascinating individuals in the world of healthcare and medical education.